

Supplemental Figures




Figure S1. (A) Cell cycle distribution of HeLa shCtrl cells treated with Dox and HeLa shNek1 in the absence of Dox or (B) HCT-15 cells transfected with siCtrl, irradiated with either a single dose of 2 Gy, or fractionated 3 x 2 Gy with an interval of 2 h (left), 6 h (middle) and 24 h (right) analyzed by flow cytometry (n = 3; # p < 0.05, ## p < 0.01 irradiated vs. non irradiated control).




Figure S2. (A) 3D clonogenic radiation survival following a 2, 4 or 6 Gy single dose irradiation or fractionated irradiation with 2 h (left), 6 h (middle) and 24 h fractionation interval (right) of HeLa shNek1 and shCtrl cells in the absence of Dox (means \pm SD; $n = 3$; $\wedge p < 0.05$ fractionated vs. single dose). (B) Relative tumor growth curves of NSG mice (6 animals per group) inoculated with HeLa shCtrl cells treated with (right) or without Dox (left). Mean values of tumor volumes for each treatment group are shown.

Supplemental Table 1

Table S1: Correlation of Nek1 expression with clinicopathologic characteristics. Abbreviation: FIGO: Fédération Internationale de Gynécologie et d'Obstétrique.

	No. of patients	Nek1 WS ≤ 6 n (%)	Nek1 WS > 6 n (%)	p-value
Age				
≤ 59 years	38	22 (29.7)	16 (21.6)	0.970
> 59 years	36	21 (28.3)	15 (20.2)	
T-Stage				
T1/2	39	22 (29.7)	17 (22.9)	0.288
T3/4	35	24 (32.4)	11 (14.8)	
N-Stage				
N0	39	25 (33.7)	14 (18.9)	0.652
N1	34	21 (29.3)	13 (16.5)	
Nx	1		1 (1.3)	
M-Status				
M0	63	40 (54.0)	23 (31.0)	0.579
M1	11	6 (8.1)	5 (6.9)	
FIGO				
Low (Ia-IIb)	29	18 (24.3)	11 (14.8)	0.99
High (IIIa-IVb)	45	28 (37.8)	17 (22.9)	
Grading				
G1/2	38	21 (29.3)	17 (22.9)	0.171
G3	34	23 (31.0)	11 (14.8)	
Gx	2	2 (2.70)		
p16^{INK4a}				
Low (WS ≤ 6)	27	17 (22.9)	10 (13.5)	0.916
High (WS > 6)	47	29 (39.2)	18 (24.3)	